<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

    July 24, 2023

    Biodesix announced today that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7.

    Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

    July 12, 2023

    Biodesix announced today that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test [NCT03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures.

    Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

    July 6, 2023

    Biodesix announces the designation of its Nodify CDT Test as an Advanced Diagnostic Laboratory Test by CMS, recognizing its innovation and clinical value in assessing the risk of malignancy in pulmonary nodules

    Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier

    June 27, 2023

    INSIGHT study monitors 5,000 NSCLC patients for 3 years, validating VeriStrat® test. Biodesix: leading lung disease diagnostic solutions.

    Biodesix Announces First Quarter 2023 Results and Highlights

    May 11, 2023

    Biodesix reports Q1 2023 results: 86% increase in Core Lung Diagnostic revenue, record test numbers, and reaffirms 2023 financial outlook.

    Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

    June 1, 2023

    three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR)

    Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference

    May 31, 2023

    Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair’s 43rd Annual Growth Stock Conference, which will be held from June 6-8, 2023.

    Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

    May 25, 2023

    Biodesix presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules.

    Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors

    May 24, 2023

    Biodesix, Inc. is proud to announce that its CFO, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors.

    Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

    May 18, 2023

    Biodesix announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.

    1 2 3 4 5 6 7 8 9